SG11202008102VA - Cyclopentane-based modulators of sting (stimulator of interferon genes) - Google Patents
Cyclopentane-based modulators of sting (stimulator of interferon genes)Info
- Publication number
- SG11202008102VA SG11202008102VA SG11202008102VA SG11202008102VA SG11202008102VA SG 11202008102V A SG11202008102V A SG 11202008102VA SG 11202008102V A SG11202008102V A SG 11202008102VA SG 11202008102V A SG11202008102V A SG 11202008102VA SG 11202008102V A SG11202008102V A SG 11202008102VA
- Authority
- SG
- Singapore
- Prior art keywords
- sting
- stimulator
- cyclopentane
- interferon genes
- based modulators
- Prior art date
Links
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 title 2
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 title 1
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 title 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643467P | 2018-03-15 | 2018-03-15 | |
| US201862666204P | 2018-05-03 | 2018-05-03 | |
| US201862742532P | 2018-10-08 | 2018-10-08 | |
| US201962809990P | 2019-02-25 | 2019-02-25 | |
| PCT/IB2019/052009 WO2019175776A1 (en) | 2018-03-15 | 2019-03-12 | Cyclopentane-based modulators of sting (stimulator of interferon genes) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202008102VA true SG11202008102VA (en) | 2020-09-29 |
Family
ID=66103038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008102VA SG11202008102VA (en) | 2018-03-15 | 2019-03-12 | Cyclopentane-based modulators of sting (stimulator of interferon genes) |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10538542B2 (en) |
| EP (1) | EP3765474B1 (en) |
| JP (1) | JP7266942B2 (en) |
| KR (1) | KR20200131878A (en) |
| CN (1) | CN111918871A (en) |
| AU (1) | AU2019234043A1 (en) |
| BR (1) | BR112020018593A2 (en) |
| CA (1) | CA3093631C (en) |
| CL (1) | CL2020002352A1 (en) |
| CR (1) | CR20200382A (en) |
| DO (1) | DOP2020000160A (en) |
| EC (1) | ECSP20057847A (en) |
| ES (1) | ES2923298T3 (en) |
| IL (1) | IL277278A (en) |
| MA (1) | MA52012A (en) |
| MX (1) | MX2020009587A (en) |
| NI (1) | NI202000058A (en) |
| PE (1) | PE20210412A1 (en) |
| PH (1) | PH12020551486A1 (en) |
| RU (1) | RU2020130048A (en) |
| SG (1) | SG11202008102VA (en) |
| TW (1) | TWI741268B (en) |
| UY (1) | UY38145A (en) |
| WO (1) | WO2019175776A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7098748B2 (en) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | 2'3'cyclic dinucleotide with phosphonate binding that activates the STING adapter protein |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| TWI833744B (en) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-cyclic dinucleotides |
| TW202028179A (en) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | Amino acid compounds and methods of use |
| JP2022550297A (en) * | 2019-09-25 | 2022-12-01 | ファイザー・インク | Heteropolycyclic modulators of STING (interferon gene stimulator) |
| KR20220167275A (en) | 2020-04-10 | 2022-12-20 | 오노 야꾸힝 고교 가부시키가이샤 | cancer treatment methods |
| US11964978B2 (en) * | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (en) | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| ES2692226T3 (en) | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Cyclic dinucleotides as STING modulators |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
-
2019
- 2019-03-11 US US16/297,910 patent/US10538542B2/en active Active
- 2019-03-11 TW TW108108048A patent/TWI741268B/en not_active IP Right Cessation
- 2019-03-12 WO PCT/IB2019/052009 patent/WO2019175776A1/en active Application Filing
- 2019-03-12 CN CN201980019494.9A patent/CN111918871A/en active Pending
- 2019-03-12 CA CA3093631A patent/CA3093631C/en active Active
- 2019-03-12 SG SG11202008102VA patent/SG11202008102VA/en unknown
- 2019-03-12 KR KR1020207029472A patent/KR20200131878A/en not_active Application Discontinuation
- 2019-03-12 EP EP19717149.9A patent/EP3765474B1/en active Active
- 2019-03-12 MX MX2020009587A patent/MX2020009587A/en unknown
- 2019-03-12 RU RU2020130048A patent/RU2020130048A/en unknown
- 2019-03-12 ES ES19717149T patent/ES2923298T3/en active Active
- 2019-03-12 CR CR20200382A patent/CR20200382A/en unknown
- 2019-03-12 JP JP2020548916A patent/JP7266942B2/en active Active
- 2019-03-12 PE PE2020001412A patent/PE20210412A1/en unknown
- 2019-03-12 AU AU2019234043A patent/AU2019234043A1/en not_active Abandoned
- 2019-03-12 BR BR112020018593-0A patent/BR112020018593A2/en not_active IP Right Cessation
- 2019-03-12 MA MA052012A patent/MA52012A/en unknown
- 2019-03-13 UY UY38145A patent/UY38145A/en not_active Application Discontinuation
- 2019-12-04 US US16/702,738 patent/US10968242B2/en active Active
-
2020
- 2020-08-25 DO DO2020000160A patent/DOP2020000160A/en unknown
- 2020-08-28 NI NI202000058A patent/NI202000058A/en unknown
- 2020-09-10 IL IL277278A patent/IL277278A/en unknown
- 2020-09-11 CL CL2020002352A patent/CL2020002352A1/en unknown
- 2020-09-12 PH PH12020551486A patent/PH12020551486A1/en unknown
- 2020-09-15 EC ECSENADI202057847A patent/ECSP20057847A/en unknown
-
2021
- 2021-03-03 US US17/190,924 patent/US20210230196A1/en not_active Abandoned
-
2023
- 2023-07-24 US US18/225,589 patent/US20230382932A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277278A (en) | Cyclopentane-based modulators of sting (stimulator of interferon genes) | |
| IL276844A (en) | Agonists of stimulator of interferon genes sting | |
| ZA201904311B (en) | Cyclic dinucleotides as sting (stimulator of interferon genes) agonists | |
| IL272928A (en) | Cyclic di-nucleotides as stimulator of interferon genes modulators | |
| ZA201908496B (en) | Small molecule modulators of human sting | |
| HK1247089A1 (en) | Copositions and methods for activing "stimulator of interferon gene"-dependent signalling | |
| EP3585379A4 (en) | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | |
| IL288868A (en) | Next-generation modulators of stimulator of interferon genes (sting) | |
| IL291650A (en) | Polyheterocyclic modulators of sting (stimulator of interferon genes) | |
| IL281492A (en) | Modulators of pnpla3 expression | |
| GB201709959D0 (en) | Small molecule modulators of human STING | |
| IL272373A (en) | Factor viii (fviii) gene therapy methods | |
| IL283967A (en) | Modulators of hsd17b13 expression | |
| EP3410996A4 (en) | Reproducible placement of abi electrodes | |
| IL290772A (en) | Monocyclic agonists of stimulator of interferon genes sting | |
| IL277847A (en) | Modulators of ezh2 expression | |
| IL290771A (en) | Bicyclic agonists of stimulator of interferon genes sting | |
| GB201905301D0 (en) | Gene therapy | |
| GB201817470D0 (en) | Gene therapy | |
| GB201802326D0 (en) | Gene therapy | |
| IL285333A (en) | Modulators of malat1 expression | |
| IL280531A (en) | Gene therapy methods to control organ function | |
| EP3760209C0 (en) | Ischemic-lesion-site-specific gene therapy | |
| GB201810172D0 (en) | Azaheteocyclic small molecule modulators of human sting | |
| GB201811541D0 (en) | Gene therapy |